Comment on

• A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.

  Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. Khanna D, et al. Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548. Arthritis Rheum. 2011. PMID: 21769849 Free PMC article. Clinical Trial.
• Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

  Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K. Pope J, et al. Arthritis Rheum. 2011 Nov;63(11):3547-51. doi: 10.1002/art.30549. Arthritis Rheum. 2011. PMID: 21769850 Clinical Trial.